Connect Biopharma reports Phase 2 asthma topline: +130 mL FEV1 vs placebo; 66% lower treatment failures
Connect Biopharma reported Phase 2 topline: rademikibart gave a 130 mL greater FEV1 increase vs placebo at Day 7 and a 66% reduction in 28-day treatment failures (not statistically significant for primary endpoint).Key Highlights:Original SEC Filing: Connect Biopharma Holdings Ltd [ CNTB ] - 8-K…
This is a real-time flash headline. A verified provider body is not available, so SquawkNews does not present it as a full article.